On Thursday, DMK Pharmaceuticals Corporation (DMK) experienced a significant increase in share price, with a 17% rise, following an announcement that the company has regained full rights to commercialize ZIMHI (naloxone).
DMK is trading on the Nasdaq at $0.70, up 18.67% or $0.11 per share. It has traded between $0.45 and $21.70 in the past 52-week period.
This comes after the termination of an exclusive commercialization and distribution agreement with US WorldMeds, LLC. As a result, DMK is now actively pursuing commercialization opportunities for ZIMHI in the United States, Canada, and Europe, with a focus on generating new and near-term revenues.
ZIMHI is primarily targeted toward first responders in the United States, although the company is exploring additional opportunities for commercialization in other markets as well.
With full control over the commercialization and distribution of ZIMHI, DMK is well-positioned to capitalize on the growing demand for this life-saving medication, which is used to quickly reverse the effects of fentanyl (opioid) overdose.
For comments and feedback: editorial@rttnews.com